Mumbai-based ENTOD Pharmaceuticals has secured approval for PresVu Eye Drops, a groundbreaking treatment for presbyopia that could eliminate the need for reading glasses.
The eye drops are designed to provide a non-invasive solution for people suffering from this age-related condition that affects the ability to focus on close objects.
Presbyopia, which usually begins in the mid-40s and worsens until the late 60s, affects between 1.09 billion and 1.80 billion people globally.
ENTOD Pharmaceuticals’ innovative product has received final approval from the Drug Controller General of India (DCGI) after being recommended by the Central Drugs Standard Control Organisation’s (CDSCO) Subject Expert Committee (SEC).
A first in India
PresVu is claimed to be the first eye drop in India specifically formulated to reduce dependence on reading glasses for people with presbyopia. The company has applied for a patent for this unique formulation and its manufacturing process.
The eye drops use advanced dynamic buffer technology, allowing them to adapt to tear pH quickly. This technology ensures consistent efficacy and safety, making the drops suitable for long-term use.
"The approval of PresVu is a promising development in ophthalmology. For patients with presbyopia, this eye drop offers a non-invasive option that can enhance near vision without the need for reading glasses," said Dr Dhananjay Bakhle, highlighting the clinical potential of PresVu.
Promising alternative to glasses
Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, emphasised the significance of the approval, noting, "PresVu is the result of years of dedicated research and development.
It is more than just a product; it's a solution that stands to improve the lives of millions by offering them greater visual independence."
Dr Aditya Sethi, another expert in the field, stated that the drops could provide enhanced near vision within 15 minutes of application, making them an attractive alternative to reading glasses.
Availability and cost
PresVu will be available in pharmacies from the first week of October on a prescription basis, priced at Rs 350.
The medication is intended for people aged 40 to 55 years with mild to moderate presbyopia. Besides eliminating the need for reading glasses, the eye drops also offer the added benefit of lubricating the eyes.
Follow us
